{"url_path":"/sec/btsg/8-k/2026-06-12/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1865782/0001193125-26-269360-index.html","accession_number":"0001193125-26-269360","cik":"0001865782","ticker":"BTSG","issuer_name":"BrightSpring Health Services, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1865782/0001193125-26-269360-index.html","primary_entity_key":"0001865782","primary_entity_name":"BrightSpring Health Services, Inc."},"word_count":236,"has_tables":true,"body_markdown":"## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 11, 2026, the board of directors (the “Board”) of BrightSpring Health Services, Inc. (the “Company”) increased the number of directors serving on the Board from seven (7) to eight (8) members and appointed Dr. Nigam H. Shah to the Board as a Class III director to fill the resulting vacancy. Dr. Shah will serve until his successor shall be elected and qualified, or until his earlier death, resignation, retirement, disqualification or removal from office. The Board also appointed Dr. Shah to serve as a member of the Quality and Compliance Committee of the Board.\n\nDr. Shah will be compensated for his service as a director in accordance with the Company’s policy on non-employee director compensation. In connection with Dr. Shah’s appointment to the Board, the Company intends to enter into an indemnification agreement with Dr. Shah in substantially the same form as the Company has entered into with each of the Company’s existing directors and as previously filed with the Securities and Exchange Commission.\n\nThere are no arrangements or understandings between Dr. Shah and any other person pursuant to which he was selected as a director. There has been no transaction, nor is there any currently proposed transaction, between Dr. Shah and the Company that would require disclosure under Item 404(a) of Regulation S-K."}